News Image

Unlocking the Growth Potential of NASDAQ:AMPH.

By Mill Chart

Last update: Jan 23, 2024

In this article we will dive into AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) as a possible candidate for growth investing. Investors should always do their own research, but we noticed AMPHASTAR PHARMACEUTICALS IN showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.

Some of the growth metrics of NASDAQ:AMPH highlighted

  • AMPHASTAR PHARMACEUTICALS IN demonstrates a strong Return on Equity(ROE) of 22.72%. This indicates the company's ability to generate favorable returns for shareholders and reflects its efficient utilization of capital. AMPHASTAR PHARMACEUTICALS IN shows promising potential for continued success.
  • AMPHASTAR PHARMACEUTICALS IN has consistently exceeded EPS estimates in the last 4 quarters, demonstrating its ability to outperform market expectations. This trend highlights the company's strong financial performance and its potential for future growth.
  • With impressive 1-year revenue growth of 24.0%, AMPHASTAR PHARMACEUTICALS IN showcases its ability to generate increased sales and revenue. This growth highlights the company's strong customer demand and its effective business strategies.
  • With impressive quarter-to-quarter (Q2Q) revenue growth of 50.37%, AMPHASTAR PHARMACEUTICALS IN showcases its ability to generate increased sales and revenue. This growth indicates the company's strong customer demand and its effective business strategies.
  • With a favorable trend in its operating margin over the past year, AMPHASTAR PHARMACEUTICALS IN demonstrates its ability to enhance profitability through efficient operations. This growth reflects the company's focus on optimizing its cost structure.
  • AMPHASTAR PHARMACEUTICALS IN has shown positive growth in its free cash flow (FCF) over the past year, indicating improved cash generation and financial strength. This growth highlights the company's ability to effectively manage its cash flows and generate surplus funds.
  • The EPS of AMPHASTAR PHARMACEUTICALS IN has exhibited growth from one quarter to another (Q2Q), with a 203.0% increase. This underscores the company's ability to generate higher earnings and improve its financial standing.
  • The average next Quarter EPS Estimate for AMPHASTAR PHARMACEUTICALS IN has experienced a 23.76% change in the last 3 months, reflecting evolving expectations by analysts regarding the company's EPS performance.
  • The recent financial report of AMPHASTAR PHARMACEUTICALS IN demonstrates a 203.0% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
  • AMPHASTAR PHARMACEUTICALS IN shows accelerating EPS growth: when comparing the current Q2Q growth of 203.0% to the previous year Q2Q growth of -17.39%, we see the growth rate improving.

Fundamental Analysis Observations

ChartMill assigns a proprietary Fundamental Rating to each stock. The score is computed daily by evaluating various fundamental indicators and properties. The score ranges from 0 to 10.

Overall AMPH gets a fundamental rating of 7 out of 10. We evaluated AMPH against 205 industry peers in the Pharmaceuticals industry. AMPH scores excellent on profitability, but there are some minor concerns on its financial health. AMPH is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, AMPH could be worth investigating further for value and growth investing!.

For an up to date full fundamental analysis you can check the fundamental report of AMPH

Our Lois Navellier screen will find you more ideas suited for growth investing.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (5/24/2024, 7:13:49 PM)

After market: 43 -0.26 (-0.6%)

43.26

-0.09 (-0.21%)

AMPH News

News Image11 days ago - InvestorPlacePatent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade

The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.

News Image12 days ago - ChartmillExploring NASDAQ:AMPH's growth characteristics.

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations

News Image18 days ago - InvestorPlaceAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image18 days ago - BusinessInsiderAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amphastar Pharma (NASDAQ:AMPH) just reported results for the first quarter of 2...

News Imagea month ago - Market News VideoOversold Conditions For Amphastar Pharmaceuticals (AMPH)
News Imagea month ago - Market News VideoCommit To Buy Amphastar Pharmaceuticals At $22.50, Earn 18.5% Annualized Using Options
News Image3 months ago - Market News VideoAmphastar Pharmaceuticals Becomes Oversold (AMPH)
News Image3 months ago - Market News VideoAmphastar Pharmaceuticals (AMPH) Shares Cross Below 200 DMA
News Image3 months ago - Seeking AlphaAmphastar Pharmaceuticals Non-GAAP EPS of $0.88 misses by $0.03, revenue of $178.1M beats by $4.77M (NASDAQ:AMPH)

Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...

News Image3 months ago - Investor's Business DailyCRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

News Image4 months ago - Market News VideoAMPH Crosses Below Key Moving Average Level
News Image4 months ago - InvestorPlace3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential

As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.

AMPH Links
Follow us for more